Majority of Parkinson’s Patients Improved After German Stem Cell Treatment

Share Article

The XCell-Center, Europe’s leading stem cell therapy provider has released results from a follow-up study of 50 Parkinson’s disease patients treated with autologous bone marrow stem cells. Overall, almost 60% improved following treatment.

The XCell-Center, Europe’s leading stem cell therapy provider has released results from a follow-up study of 50 Parkinson’s disease patients treated with autologous bone marrow stem cells. Overall, almost 60% improved following treatment.

These results support the premise that patients with Parkinson’s disease can be treated safely and effectively with autologous stem cell therapy.

The most common improvements reported by patients were decreased rigidity (74%) and better walking/gait (over 80%).

“Two months after the stem cell therapy, I had a checkup for a hole in my eardrum that had been there for several years and it was healed up completely! As for the Parkinson's symptoms, I am much stronger. I still fall occasionally but nothing compared to before therapy. People tell me that I am talking much better. I am blinking and smiling and I have more facial expression… My ability to use utensils at mealtime is almost back to normal,” said Mr. Herman Engman, who was treated in January 2009.

More than half of the patients who improved reported decreased tremors while more than 60% experienced better speech. Approximately 60% of the patients surveyed had their improvement confirmed by their own physician.

Complete results are available at http://www.xcell-center.com/treatments/results/parkinson-s.aspx

“Now, I am walking like I was before I had Parkinson's and my shaking is more under control… I am sleeping longer at night and have also gained 10 pounds… This is the first time in four years that I have been able to gain any weight,” stated Mr. John Andresen. Mr. Andresen was treated in July 2009.

The treatment begins by collecting a small amount bone marrow from the patient’s hip via thin needle mini-puncture under local anesthesia. The stem cells are separated from the bone marrow at the XCell-Center’s EU certified cGMP laboratory, where they are counted and their vitality is confirmed. The last step consists of inserting a fine spinal needle between the patient’s L4 and L5 vertebrae and injecting the stem cells into the cerebrospinal fluid which flows into the brain.

The cost for Parkinson’s treatment starts at around 7,545 Euros.

In 2009, the XCell-Center treated its first patients via stereotactic autologous stem cell implantation. This innovative technique allows neurosurgeons to implant stem cells directly into a patient’s brain, thus achieving more accurate targeting of stem cells than with other implantation methods such as intrathecal injection. All XCell-Center patients are treated with their own bone marrow-derived stem cells.

About the XCell-Center
The XCell-Center operates treatment centers in Cologne and Dusseldorf, Germany. It is the first privately-owned clinic in Europe to specialize in regenerative medicine using autologous bone marrow stem cell therapy and operates in accordance with German law, European guidelines and ISO 9001. Its specialized medical team of German physicians includes specialists in: neurosurgery, orthopedics, cardiology, radiology, anesthesiology and pharmacology.

The XCell-Center also treats Diabetes and its complications (Erectile Dysfunction and Peripheral Artery Disease), Stroke, Cerebral Palsy, Autism, Spinal Cord Injuries, Orthopedic diseases, Heart Disease and degenerative diseases such as Multiple Sclerosis, Parkinson's, Alzheimer's and several eye diseases.

For more information on Stem Cell Therapy:

XCell-Center Website: http://www.xcell-center.com

XCell-Center GmbH
at the Institute for Regenerative Medicine
Am Heerdter Krankenhaus 2
40549 Dusseldorf, Germamy

E-Mail: info(at)xcell-center(dot)de

Phone: 1-866-680-8202 (USA Toll-Free)    (+49) 0221-802-5095 (Germany)

Fax:        1-713-583-9322 (USA)     (+49) 0221-2921-2550 (Germany)

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jay D. Lenner Jr.
Visit website